## Figure 2

### IT and research are the most popular investment areas for generative artificial intelligence in pharma

**Percentage of executives who report reaching the stage of development by**

- Gray: Ideation or selected as a priority use case
- Light Red: Proof of concept in development or developed
- Medium Red: Active pilot testing or minimum viable product build
- Dark Red: Full rollout or implementation

|                                              |                                                |                              |                              |                                                           |                                       |
|----------------------------------------------|------------------------------------------------|------------------------------|------------------------------|-----------------------------------------------------------|---------------------------------------|
| **IT**                                       | **Research**                                   | **Biomedical literature review** | **Competitive intelligence** | **Sales or medical affairs contact center automation** | **Marketing**                        |
| ![Chart](chart_placeholder)                  | ![Chart](chart_placeholder)                    | ![Chart](chart_placeholder)  | ![Chart](chart_placeholder)  | ![Chart](chart_placeholder)                              | ![Chart](chart_placeholder)          |

Source: Bain Generative Artificial Intelligence in Pharma Survey, September 2023 (N=100)